Chloride voltage-gated channel 3 (CLCN3) (CLCN3)

Chloride voltage-gated channel 3 (CLCN3), also known as ClC-3, is a member of the voltage-gated chloride channel family that primarily functions as an electrogenic 2Cl-/H+ exchanger [UniProt, NIH]. It is predominantly localized in the membranes of intracellular organelles such as endosomes, lysosomes, and synaptic vesicles, where it plays a critical role in luminal acidification and ion homeostasis [UniProt, Wikipedia]. CLCN3 is also found on the plasma membrane, contributing to volume-regulated chloride currents (VRAC/VRCC) that are essential for cell volume regulation, proliferation, and migration [NIH, Frontiers]. In pathology, CLCN3 is frequently overexpressed in various cancers, including glioma and ovarian cancer, where it promotes tumor invasion, metastasis, and resistance to chemotherapy [NIH, Oncotarget]. Conversely, loss-of-function mutations in humans are linked to neurodevelopmental disorders characterized by hypotonia and brain abnormalities, while Clcn3-deficient mice exhibit severe hippocampal and retinal degeneration [NIH, UniProt]. Although specific clinical drugs targeting CLCN3 are currently lacking, non-specific inhibitors like DIDS and tamoxifen, as well as the peptide chlorotoxin, have been used in research to modulate its activity [NIH, MDPI]. Targeting CLCN3 represents a promising therapeutic strategy for treating aggressive cancers and atherosclerosis, though safety concerns regarding neurotoxicity must be carefully managed [NIH].

Other names

ClC-3CLC3Chloride channel protein 3H(+)/Cl(-) exchange transporter 3Chloride transporter ClC-3

Inhibition of chloride/proton exchange and volume-regulated chloride currents to suppress cell proliferation, migration, and invasion in cancer and atherosclerosis; or activation to induce apoptosis and sensitize cells to chemotherapy [NIH, MDPI].